Table 1.
Characteristics of acute GvHD patients and treatment
| Patient Number | Birth Date | Diagnostic (Stage at Treatment) | Treatment | Date of transplantation | GvHD Prophylaxis | Donor |
|---|---|---|---|---|---|---|
| Sk‐HEP1 cells exposed during 48 h to a sera pool from three patients (P1, P2, P3) developing GvHD between day 7 and day 14. Sample from day 14. | ||||||
| Patient 1 | 09‐01‐1971 | Follicular Non‐Hodgkin's lymphoma | Cyclosporine A/Total Body Irradiation | 15‐09‐2008 | Cyclosporine A/Methotrexate | Non‐related |
| Patient 2 | 02‐01‐1980 | Hodgkin's disease: nodular sclerosis | Fludarabine/Melphalan | 21‐08‐2009 | Cyclosporine A | Non‐related |
| Patient 3 | 23‐09‐1988 | Non‐Hodgkin's lymphoma: Primary mediastinal large B cell | BEAM200 (BCNU‐Etoposide100‐Ara‐C‐Melphalan) | 29‐04‐2009 | Cyclosporine A/Methotrexate | Non‐related |
| Sk‐HEP1 cells exposed during 48 h to a sera pool from three patients (P4, P5, P6) developing GvHD between day 15 and day 21. Sample from day 21. | ||||||
| Patient 4 | 05‐05‐1975 | Acute myeloid leukaemia subtype M5 (AML‐M5) | Cyclosporine A/Total Body Irradiation | 28‐08‐2009 | Cyclosporine A/Methotrexate | Identical sibling |
| Patient 5 | 23‐09‐1988 | Non‐Hodgkin's lymphoma: Primary mediastinal large B cell | BEAM200 (BCNU‐Etoposide100‐Ara‐C ‐ Melphalan) | 29‐04‐2009 | Cyclosporine A/Methotrexate | Non‐related |
| Patient 6 | 28‐02‐1983 | Hodgkin's disease: nodular sclerosis | Fludarabine/Melphalan | 18‐06‐2008 | Cyclosporine A/Mycophenolate mofetil | Non‐related |
| Sk‐HEP1 cells exposed during 48 h to a sera pool from three patients (P7, P8, P9) developing GvHD between day 7 and day 14. Sample from day 14. | ||||||
| Patient 7 | 19‐01‐1959 | Biphenotypic Leukaemia (Relapse) | FLAG (Fludarabine‐ Ara‐C ‐G‐CSF)/IDA (idarubicin)/Melphalan | 10‐03‐2009 | Cyclosporine A/Mycophenolate mofetil | Non‐related |
| Patient 8 | 27‐04‐1957 | Non‐Hodgkin's lymphoma: unclassified | BEAM200 (BCNU‐Etoposide100‐Ara‐C‐Melphalan | 16‐12‐2009 | Cyclosporine A/Mycophenolate mofetil | Non‐related |
| Patient 9 | 17‐03‐1995 | Chronic lymphocytic leukaemia | BEAM200 (BCNU‐Etoposide100‐Ara‐C‐Melphalan | 20‐07‐2009 | Cyclosporine A/Mycophenolate mofetil | Non‐related |
| Sk‐HEP1 cells exposed during 48 h to a sera pool from three patients (P10, P11, P12) developing GvHD between day 14 and day 21. Sample from day 21. | ||||||
| HUVEC cells exposed during 48 h to a sera pool from four patients (P10, P11, P12, P13) developing GvHD between day 7 and day 14. Sample from day 14. | ||||||
| Patient 10 | 27‐03‐1968 | Acute myeloid leukaemia subtype M5 (AML‐M5) | FLAG (Fludarabine‐Ara‐C ‐GCSF)/IDA (idarubicin)/Melphalan | 31‐10‐2008 | Cyclosporine A/Mycophenolate mofetil | Identical sibling |
| Patient 11 | 19‐12‐1948 | Acute myeloid leukaemia subtype M1 (AML‐M1) (1st remission) | Fludarabine/Busulfan | 22‐04‐2009 | Cyclosporine A/Rapamycin | Identical sibling |
| Patient 12 | 03‐02‐1988 | Acute myeloid leukaemia subtype M3 (AML‐M3) | Cyclosporine A/Total Body Irradiation | 31‐10‐2008 | Cyclosporine A/Methotrexate | Identical sibling |
| Patient 13 | 22‐04‐1958 | Diffuse large B cell lymphoma | Fludarabine/Cyclosporine A/Melphalan/Total Body Irradiation | 11‐01‐2019 | Cyclosporine A/Tacrolimus/Mycophenolate mofetil | Identical sibling |
| Sk‐HEP1 cells exposed during 48 h to a sera pool from 3 patients (P13, P14, P15) developing GvHD between day 22 and day 28. Sample from day 28. | ||||||
| Patient 14 | 20‐10‐1981 | Hodgkin's disease: nodular sclerosis | Fludarabine/Melphalan | 01‐12‐2009 | Cyclosporine A/Rapamycin/Melphalan | Identical sibling |
| Patient 15 | 06‐01‐1968 | Acute lymphoblastic leukaemia: T cell | Cyclosporine A/Total Body Irradiation | 17‐07‐2008 | Cyclosporine A/Methotrexate | Non‐related |
| Patient 16 | 14‐04‐1979 | Multiple myeloma | Fludarabine/Melphalan | 03‐03‐2009 | Cyclosporine A/Mycophenolate mofetil | Non‐related |